Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0018681 (
headache
)
56,091
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cluster headache and the other trigeminal-autonomic cephalalgias [paroxysmal hemicrania, short-lasting unilateral neuralgiform
headache
attacks with conjunctival injection and tearing (SUNCT) syndrome] are rare but very disabling conditions with a major impact on the patient's quality of life. The objective of this study was to give evidence-based recommendations for the treatment of these
headache
disorders based on a literature search and consensus amongst a panel of experts. All available medical reference systems were screened for any kind of studies on cluster
headache
, paroxysmal hemicrania and
SUNCT syndrome
. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies resulting in level A, B or C recommendations and good practice points. For the acute treatment of cluster
headache
attacks, oxygen (100%) with a flow of at least 7 l/min over 15 min and 6 mg subcutaneous sumatriptan are drugs of first choice. Prophylaxis of cluster
headache
should be performed with verapamil at a daily dose of at least 240 mg (maximum dose depends on efficacy or tolerability). Although no class I or II trials are available, steroids are clearly effective in cluster
headache
. Therefore, the use of at least 100 mg methylprednisone (or equivalent corticosteroid) given orally or at up to 500 mg i.v. per day over 5 days (then tapering down) is recommended. Methysergide, lithium and topiramate are recommended as alternative treatments. Surgical procedures, although in part promising, require further scientific evaluation. For paroxysmal hemicranias, indomethacin at a daily dose of up to 225 mg is the drug of choice. For treatment of
SUNCT syndrome
, large series suggest that lamotrigine is the most effective preventive agent, with topiramate and gabapentin also being useful. Intravenous lidocaine may also be helpful as an acute therapy when patients are extremely distressed and disabled by frequent attacks.
...
PMID:EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. 1698 58
Following the revised International
Headache
Society criteria, a group of short-lasting
headaches
associated with autonomic symptoms, the so called trigeminal autonomic cephalgias, were newly recognized. The trigeminal autonomic cephalgias include cluster
headache
, paroxysmal hemicranias and a syndrome involving short-lasting unilateral neuralform cephalgias with conjunctival injection and tearing (SUNCT) syndrome. In all of these syndromes, the half-sided
head pain
and cranial autonomic symptoms are prominent. All of the trigeminal autonomic cephalgias differ in duration, frequency and rhythmicity of the attacks, the intensity of pain and autonomic symptoms, as well as treatment options. This review gives a brief clinical description of the
headache
disorders and recent pathophysiological findings, as well as an overview of the treatment of cluster
headache
, paroxysmal hemicranias and
SUNCT syndrome
.
...
PMID:Trigeminal-autonomic headaches in daily clinical practice. 1707 92
SUNCT is a rare condition characterised by a short-lasting periorbital pain associated with autonomic symptoms and is usually unresponsive to pharmacological treatment. We report a case of
SUNCT syndrome
linked to a pituitary micro-adenoma, with only nocturnal attacks. The nocturnal levels of prolactin (PRL) were increased, while other hormonal, haematological, serological and biochemical investigations and levels of PRL did not reveal abnormal findings during the day-time. PRL serum secretion after thyrotropin-releasing hormone test was lower than nocturnal secretion, but not enough to induce severe attacks. We suggest that in our patient the rise of nocturnal levels of PRL could have a direct role in the worsening of this
headache
, perhaps secondarily to an altered regulation of the hypothalamic-hypophysial axis, however the actual influence of sleep and the interaction between all neurotransmitters and hormones needs to be clarified further.
J
Headache
Pain 2007 Apr
PMID:SUNCT and high nocturnal prolactin levels: some new unusual characteristics. 1749 64
SUNCT syndrome
is a rare form of a primary
headache
disorder, although secondary causes, particularly posterior fossa abnormalities, are well known. We report a new case in a 67-year-old man suffering
SUNCT syndrome
secondary to pyogenic cerebral abscess and empyema localized in the convexity portion of the right frontal lobe.
...
PMID:[Symptomatic SUNCT with cerebral abscess and subdural empyema]. 1787 10
SUNCT is one of the rarest and least known primary
headache
disorders. Although its pathogenesis has been partially understood by functional neuroimaging and reports of secondary cases, there is limited understanding of its cause. We report a case of SUNCT in a 54-years-old man, that could not be strictly classified as secondary SUNCT; however, the time lag of pain onset suggests a new theory in which neuroplasticity could be involved in the origin and duration of the pain in
SUNCT syndrome
.
...
PMID:SUNCT syndrome: report of a possible symptomatic case. 1795 96
We describe a 46-year-old female with viral meningoencephalitis (likely varicella-zoster virus) who developed a
SUNCT syndrome
followed a few days later by trigeminal neuralgia. Both disorders resolved in parallel with the resolution of encephalitis, which suggests a causal link. In conclusion,
headache
attributed to intracranial infection may have the clinical features of SUNCT or TN.
J
Headache
Pain 2008 Feb
PMID:SUNCT and trigeminal neuralgia attributed to meningoencephalitis. 1821
Trigeminal autonomic cephalalgias (TACs) are a group of primary
headache
disorders, which are characterized by strictly unilateral pain, together with ipsilateral cranial autonomic symptoms. TACs include cluster
headache
(CH), paroxysmal hemicrania (PH) and short-lasting unilateral neuralgiform
headache
attacks with conjunctival injection and tearing (
SUNCT syndrome
). These diseases all have one thing in common: an activation of trigeminal nociceptive afferentia with a reflex-like activation of cranial autonomic efferentia via the facial nerve. TACs show differences not only in the length and frequency of attacks but also in the response to drug treatment. It is important to recognize and differentiate between these syndromes because they react very well, but very selectively to therapy.
...
PMID:[Pathophysiology and treatment of trigeminal autonomic cephalalgias]. 1825 66
Short-lasting, unilateral neuralgiform
headache
attacks with conjunctival injection and tearing (SUNCT) syndrome was first described in 1978 as one of the trigeminal autonomic cephalgias. In this paper the authors present a patient with a growth hormone-secreting pituitary adenoma who experienced resolution of
SUNCT syndrome
after transsphenoidal tumor resection.
...
PMID:Short-lasting, unilateral neuralgiform headache attacks with conjunctival injection and tearing syndrome treated successfully with transsphenoidal resection of a growth hormone-secreting pituitary adenoma. 1859 Apr 41
SUNCT Syndrome
(short-lasting unilateral neuralgiform
headache
with conjuntival injection and tearing) combines neuralgic, migraineus and autonomic
headaches
, three of four primary ones described in the International Classification of the IHS (International
Headache
Society). This work describes a paediatric case evaluated under MIDAS score in which a new therapeutic approach with topiramate (TPM) was used.
...
PMID:[SUNCT syndrome (short-lasting unilateral neuralgiform headache with conjuntival injection and tearing): a rare case in a paediatric patient with favourable response to topiramate]. 1863 33
Cluster headache (CH) is a primary
headache
disease characterized by recurrent short-lasting attacks (15 to 180 minutes) of excruciating unilateral periorbital pain accompanied by ipsilateral autonomic signs (lacrimation, nasal congestion, ptosis, miosis, lid edema, redness of the eye). It affects young adults, predominantly males. Prevalence is estimated at 0.5-1.0/1,000. CH has a circannual and circadian periodicity, attacks being clustered (hence the name) in bouts that can occur during specific months of the year. Alcohol is the only dietary trigger of CH, strong odors (mainly solvents and cigarette smoke) and napping may also trigger CH attacks. During bouts, attacks may happen at precise hours, especially during the night. During the attacks, patients tend to be restless. CH may be episodic or chronic, depending on the presence of remission periods. CH is associated with trigeminovascular activation and neuroendocrine and vegetative disturbances, however, the precise cautive mechanisms remain unknown. Involvement of the hypothalamus (a structure regulating endocrine function and sleep-wake rhythms) has been confirmed, explaining, at least in part, the cyclic aspects of CH. The disease is familial in about 10% of cases. Genetic factors play a role in CH susceptibility, and a causative role has been suggested for the hypocretin receptor gene. Diagnosis is clinical. Differential diagnoses include other primary
headache
diseases such as migraine, paroxysmal hemicrania and
SUNCT syndrome
. At present, there is no curative treatment. There are efficient treatments to shorten the painful attacks (acute treatments) and to reduce the number of daily attacks (prophylactic treatments). Acute treatment is based on subcutaneous administration of sumatriptan and high-flow oxygen. Verapamil, lithium, methysergide, prednisone, greater occipital nerve blocks and topiramate may be used for prophylaxis. In refractory cases, deep-brain stimulation of the hypothalamus and greater occipital nerve stimulators have been tried in experimental settings. The disease course over a lifetime is unpredictable. Some patients have only one period of attacks, while in others the disease evolves from episodic to chronic form.
...
PMID:Cluster headache. 1865 39
<< Previous
1
2
3
4
5
6
7
8
Next >>